People undergoing metabolic and bariatric surgery (MBS) are less likely to develop psychiatric disorders than those treated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs).

Lower risks for anxiety disorders, substance use disorders, cognitive deficits seen for those undergoing metabolic and bariatric surgery.

Amycretin, a new weight-loss treatment from Novo Nordisk, combines two hunger hormones, helping participants lose nearly ...

Infection, delayed kidney function, kidney loss and death are all risks associated with kidney transplant surgery in obese ...

Eli Lilly's once-weekly KwikPen format for Mounjaro has been approved in India, offering an easier delivery system for type 2 ...

As rates of MASLD, which is linked to obesity and diabetes, rise, new therapies have emerged, but better diagnostic and ...

In 2025, each issue of Population Health, Equity & Outcomes will feature a profile of a health system leader transforming ...

"These drugs have the potential to change societies, not just individuals." — Michael Le Page, New Scientist, March 29, 2025 ...

Objective: To evaluate the effect of combination therapy with pioglitazone and glucagon-like peptide (GLP)-1 in patients with type 2 diabetes. Conclusions: GLP-1 and pioglitazone show an additive ...

GLP-1 therapies primarily use single-use injectable pens, contributing to medical waste challenges. The pharmaceutical ...

In a Cleveland Clinic cohort, patients who stopped treatment for obesity had smaller weight losses to start, making these ...